{"schema_version":"secwatch.filing_event.v1","accession":"0001815776-24-000039","form_type":"8-K","ticker":"LENZ","cik":"0001815776","company_name":"LENZ Therapeutics, Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.303133+00:00","generated_at":"2026-06-02T12:28:06.996904+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"LENZ Therapeutics reports Q1 net loss $16.6M; positive Phase 3 presbyopia data, NDA on track mid-2024","bullets":["Net loss $16.6M ($3.53/share) vs $12.7M ($6.50/share) in Q1 2023; cash $213.3M.","Phase 3 CLARITY study for LNZ100 met all primary/secondary endpoints; 84% achieved ≥4 lines near vision improvement.","NDA submission to FDA for LNZ100 planned for mid-2024; commercial launch as early as H2 2025.","Completed merger with Graphite Bio and concurrent $53.5M private placement in March 2024.","Jeff George appointed Chairman; Dan Chevallard CFO; commercial buildout underway including third-party logistics."],"urls":{"canonical":"https://secwatch.observer/filing/0001815776-24-000039","json":"https://secwatch.observer/filing/0001815776-24-000039.json","markdown":"https://secwatch.observer/filing/0001815776-24-000039.md","text":"https://secwatch.observer/filing/0001815776-24-000039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815776/000181577624000039/0001815776-24-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815776/000181577624000039/lenz-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T12:28:06.996904+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"95beeaa821247d7fc46fac47ac5d411fa84fa29c","claim":"LENZ Therapeutics, Inc. reported financial results for the quarter ended March 31, 2024.","evidence_excerpt":"On May 8, 2024, LENZ Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1815776/000181577624000039/0001815776-24-000039-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}